Phase 2
Completed N=14
Aripiprazole Augmentation of Antidepressants in PTSD
Source: ClinicalTrials.gov NCT00489866 ↗Enrolled (actual)
14
Serious AEs
0.0%
Results posted
Mar 2012
Primary outcomePrimary: Clinician Administered PTSD Scale (CAPS) — 18.6; 9.58 Units on a scale
Summary
The proposed investigation will determine the therapeutic potential of aripiprazole augmentation to a stable antidepressant regimen for reducing posttraumatic stress disorder (PTSD) symptoms, cognitive symptoms, psychotic symptoms, and depressive symptoms in veterans with PTSD.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Clinician Administered PTSD Scale (CAPS) |
18.6; 9.58 | — |
| PRIMARY Brief Assessment of Cognition in Affective Disorders (BAC-A) |
-0.41; -0.14 | — |
| PRIMARY Positive and Negative Symptoms Scale (PANSS) |
2.57; -5.1 | — |
| SECONDARY Connor-Davidson Resilience Scale (CD-RISC) |
-3.00; -2.03 | — |
| SECONDARY Beck Depression Inventory, Second Edition (BDI-II) |
8.0; 2.28 | — |
Eligibility Criteria
Inclusion Criteria
- Outpatient veterans with posttraumatic stress disorder (PTSD)
- Receiving treatment with an antidepressant at a stable dose for 4 weeks
- Male or female
- Ages 18-65 years old
Data sourced from ClinicalTrials.gov (NCT00489866). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.